Evidence map›Paper›PMID 32162095›Full record

ArticleInternational journal of hematology2020

LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.

Jian Hong, Jing Ni, Min Ruan, Mingzhen Yang, Qianggang Dong, Qingsheng Li

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jian HongDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Jixi Road No. 218, Hefei, 230022, Anhui, China.
Jing NiDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Jixi Road No. 218, Hefei, 230022, Anhui, China.
Min RuanDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Jixi Road No. 218, Hefei, 230022, Anhui, China.
Mingzhen YangDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Jixi Road No. 218, Hefei, 230022, Anhui, China.
Qianggang DongShanghai Cancer Institute, Shanghai, 200030, China.
Qingsheng LiDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Jixi Road No. 218, Hefei, 230022, Anhui, China. wshysh@sina.com.ORCID http://orcid.org/0000-0001-9870-7271
Anhui Medical University · CNShanghai Cancer Institute · CN

Funding

Provincial Natural Science Research Project of Colleges and Universities in Anhui Province KJ2017A834Young Scholar Program of The First Affiliated Hospital of Anhui Medical University 2019kj20
6 · The paper itself

Abstract

Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) represent a promising treatment option for EBV-associated post-transplantation lymphoproliferative disorders (PTLD). However, production of EBV-CTLs is often complicated and expensive. In the present study, we sought to establish an easy-to-use and economical production protocol for EBV-CTLs. EBV-CTLs were generated using latent membrane protein 1 (LMP1) peptides based on a modified generation protocol of cytokine-induced killer (CIK) cells. After 2-week culture, cells were well expanded (median total cell number: 9.82 × 10

Indexed as

Cytokine-Induced Killer CellsHerpesvirus 4, HumanT-Lymphocytes, CytotoxicViral Matrix ProteinsAdolescentAnemia, AplasticEpstein-Barr Virus InfectionsFemaleHematopoietic Stem Cell TransplantationHemoglobinuria, ParoxysmalHumansImmunotherapy, AdoptiveLymphoproliferative DisordersSyndromeTreatment OutcomeEBV-associated membrane antigen, Epstein-Barr virusViral Matrix ProteinsAdoptive T cell therapyCytokine-induced killer cellsEpstein–Barr virusGeneration protocolLatent membrane protein 1

Identifiers

PMID32162095
OpenAlexW3011359830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.